ACADIA price target raised to $42 from $28 at Piper Jaffray

theflyonthewall.com

Piper Jaffray raised its price target for ACADIA Pharmaceuticals to $42 citing the company's pipeline progress following its Q4 results. The firm keeps an Overweight rating on the stock.

Rates

View Comments (0)